PDS Biotechnology (NASDAQ:PDSB) Issues Earnings Results

PDS Biotechnology (NASDAQ:PDSB) posted its quarterly earnings results on Thursday. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05), FiscalAI reports.

PDS Biotechnology Trading Down 3.6%

PDSB stock traded down $0.01 during trading on Thursday, reaching $0.23. 4,341,205 shares of the stock traded hands, compared to its average volume of 959,250. The firm has a market capitalization of $13.04 million, a PE ratio of -0.35 and a beta of 1.62. The company has a debt-to-equity ratio of 2.73, a current ratio of 2.26 and a quick ratio of 2.26. The business’s 50 day moving average price is $0.80 and its 200-day moving average price is $0.86. PDS Biotechnology has a 52-week low of $0.22 and a 52-week high of $1.55.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a research report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research report on Friday, July 17th. Finally, Wall Street Zen raised shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $9.00.

Hedge Funds Weigh In On PDS Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the company. Armistice Capital LLC acquired a new stake in PDS Biotechnology during the 4th quarter worth approximately $2,182,000. Geode Capital Management LLC lifted its position in PDS Biotechnology by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after buying an additional 38,399 shares in the last quarter. Squarepoint Ops LLC grew its stake in PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock worth $295,000 after buying an additional 156,662 shares during the period. Commonwealth Equity Services LLC grew its stake in PDS Biotechnology by 117.5% during the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after buying an additional 106,300 shares during the period. Finally, Susquehanna International Group LLP grew its stake in PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after buying an additional 80,937 shares during the period. 26.84% of the stock is owned by institutional investors and hedge funds.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.